SYNGENE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.2
| Stock Code | SYNGENE | Market Cap | 18,604 Cr. | Current Price | 462 ₹ | High / Low | 729 ₹ |
| Stock P/E | 51.5 | Book Value | 117 ₹ | Dividend Yield | 0.27 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 452 ₹ | DMA 200 | 540 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 53.4 | MACD | 9.82 | Volume | 5,21,266 | Avg Vol 1Wk | 8,65,617 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -6.11 | Debt to equity | 0.04 |
| 52w Index | 23.4 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.5 |
📊 Chart Analysis: SYNGENE is trading at ₹462, slightly above its 50 DMA (₹452) but below its 200 DMA (₹540), showing mixed signals. RSI at 53.4 suggests neutral momentum. MACD at 9.82 is positive, indicating mild bullish momentum. Bollinger Bands show price near the mid-range, reflecting consolidation. Current volume (5.21L) is below the 1-week average (8.65L), suggesting reduced participation.
📈 Momentum Signals: Short-term momentum is moderately bullish, supported by MACD and price above the 50 DMA. RSI indicates room for further upside before overbought conditions.
💹 Support & Resistance: Strong support lies near ₹452 (50 DMA) and ₹380 (recent low). Immediate resistance is at ₹540 (200 DMA) and major resistance at ₹729 (recent high). Optimal entry zone: ₹455–₹465. Exit zone: ₹525–₹540.
🔄 Trend Status: The stock is currently consolidating upward, with potential to trend higher if resistance at ₹540 is breached.
Positive
- ✅ EPS of ₹7.57 supports valuation strength.
- ✅ ROCE of 10.0% and ROE of 7.74% show moderate efficiency.
- ✅ Very low debt-to-equity ratio of 0.04 indicates financial stability.
- ✅ PAT improved sequentially from ₹68.7 Cr. to ₹154 Cr.
- ✅ DII holdings increased by 0.61%, showing domestic investor confidence.
Limitation
- ⚠️ Current price below 200 DMA, showing weak medium-term strength.
- ⚠️ High P/E of 51.5 compared to industry P/E of 39.5, suggesting premium valuation.
- ⚠️ PEG ratio of -6.11 indicates poor growth expectations.
- ⚠️ Volume below average, reflecting weak participation.
Company Negative News
- 📉 FII holdings decreased by -1.05%, showing reduced foreign investor confidence.
- 📉 Quarterly profit variation of -11.8% highlights earnings pressure.
- 📉 Stock trading at only 23.4% of its 52-week index, reflecting underperformance.
Company Positive News
- 📈 PAT more than doubled sequentially, showing operational improvement.
- 📈 Domestic institutional investors increased holdings, signaling confidence.
Industry
- 💊 Pharma & biotech sector trading at industry P/E of 39.5, lower than SYNGENE’s P/E of 51.5, suggesting premium valuation.
- 💊 Sector supported by global demand for research services and innovation in drug development.
Conclusion
📌 SYNGENE is consolidating upward, trading above the 50 DMA but below the 200 DMA. Entry around ₹455–₹465 with exit near ₹525–₹540 offers a cautious setup. Fundamentals show improving profits and low debt, but high valuation multiples, weak growth expectations, and foreign investor outflows are concerns. The stock may trend higher if resistance at ₹540 is breached.
For broader context, you could explore a biotech sector outlook or compare SYNGENE with peers through a valuation comparison.